0.5mg Wegovy Not Working: What's Really Happening and What to Do

Why the 0.5mg dose rarely produces visible weight loss on its own

Semaglutide's titration schedule exists primarily to protect your gut, not to treat your weight. Starting at 0.25mg and moving to 0.5mg gives your body time to adjust to a GLP-1 receptor agonist before the dose reaches a level where appetite suppression becomes clinically meaningful. The STEP 1 trial, published in the New England Journal of Medicine, recorded average weight reduction of around 15%, but that was at 2.4mg, across 68 weeks, in people who had reached and sustained the full maintenance dose. Sub-therapeutic doses were never the comparison point.

So if the scale hasn't moved much since you started 0.5mg, the honest answer is: it probably wasn't supposed to yet. Some people do notice a modest reduction in appetite by this stage, and a small number lose a little weight early. Others feel almost nothing different. Both are normal. The decision you're actually making right now isn't whether Wegovy works, it's whether to give the titration process the time it needs to reach a dose where it can.

If you're unsure how the full titration journey is meant to feel, a closer look at the early weeks on Wegovy can help set realistic expectations from the outset.

When to suspect a real obstacle rather than an early-stage plateau

There is a difference between "0.5mg isn't working" and "something is genuinely interfering with treatment." A few things are worth thinking through honestly before assuming the medicine is the problem.

Diet and timing both matter more than most people expect. Semaglutide slows gastric emptying, so larger, high-fat meals can cause significant nausea, which sometimes leads people to eat erratically or snack more than they realise to manage discomfort. If your eating pattern shifted when the nausea started, total calorie intake may not have fallen in the way the medicine was designed to support.

Certain medications can blunt weight-loss response too. Antidepressants, antipsychotics, corticosteroids, and some diabetes medicines are among those that can counteract the metabolic effects of semaglutide. This is a conversation for your prescriber, not a reason to stop anything unilaterally.

Stress and sleep are less obvious but clinically relevant. Elevated cortisol from chronic stress actively promotes fat storage, and poor sleep disrupts the hunger hormones that GLP-1 medicines are partly working through. A medicine managing one system while another pulls against it won't show its full effect.

The reasons Wegovy may not be working span a wider range of factors than many people realise, worth reading if you want to understand the full picture before your next clinical conversation.

The clinical benchmark for genuine non-response, and what happens next

NICE's guidance on semaglutide sets a specific and important standard: if a person achieves less than 5% weight loss after six months on the maintenance dose, continuing treatment should be reviewed. That benchmark is six months at 2.4mg, not six months from the first pen. If you're at 0.5mg and still titrating, the clock for that assessment hasn't started yet.

This matters because abandoning treatment at an early dose is one of the most common reasons people conclude Wegovy "doesn't work for them" when they haven't yet had the chance to find out. NICE's appraisal of semaglutide (TA875) is clear on this structure, and it's worth understanding before drawing conclusions at an intermediate step.

If you're approaching or already at 2.4mg and genuinely not seeing movement, that's a different conversation, and the right place for it is with a prescriber who can review your full picture. You can explore why semaglutide may not be producing results for a broader look at the evidence. Some people find titration onto a higher dose, or a discussion about switching to a dual-agonist medicine, is the more appropriate clinical path.

It's also worth checking whether the issue is specific to this dose step. Questions about 1.0mg not working are common at the next stage for the same reasons, expectations running ahead of where the titration actually is. Timing is often the real variable people underestimate, including the practical reality that hitting a dose-increase week over a bank holiday or a payday-adjacent busy patch can delay things by a week or two without anyone realising.

How to have a productive conversation with your prescriber about this

Coming to a clinical review with "it's not working" on its own doesn't give a prescriber much to work with. Coming with specifics does. Think about: how much weight you've lost or gained since starting; whether appetite has changed at all, even slightly; any side effects that altered your eating; medications you take alongside Wegovy; and how consistent your eating and activity have been.

A prescriber can then assess whether you're at a normal early stage, whether titration should continue as planned, whether there's an interaction worth addressing, or whether the clinical picture points toward a different approach entirely. If you want to understand the broader pattern of why Wegovy is not working for some people at this stage, it covers the evidence clearly and is worth reading before your next review. At nume, our clinical team reviews every consultation personally, a real prescriber reads your answers, not a questionnaire bot. If you haven't yet started treatment and want that kind of oversight from the beginning, a free consultation takes a few minutes to begin.

For a grounded overview of how Wegovy works and what the treatment journey typically looks like, the Wegovy treatment page covers the full picture in one place.